Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...

Enphase Energy (ENPH [ was the most shorted S&P 500 (SP500 [ stock as a percentage of float in May, while Super Micro Computer (SMCI [ which was at the top spot the in April, was at third position for ...

Following the release of upbeat data and given some recent signs of stabilization in the stocks, MarketWatch took at look at companies in the healthcare sector that are expected to produce the fastest ...

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations ... sell or hold the ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

Visit a quote page and your recently viewed tickers will be displayed here. Corinne Le Goff currently works at Pacific Council on International Policy, as Director from 2019, Leem, as Director, ...

It’s hard to believe Moderna (MRNA) once had a market cap exceeding $204 billion. That was in August 2021 at or near the height of the COVID-19 pandemic. As a result of Moderna possessing ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

as seen in the chart below. During this timeframe, the stock also underperformed the broader Medical sector and the S&P 500. Shares of Moderna are currently trading below their 200-day and 50-day ...